

Prevention of TGF- β -induced apoptosis by interleukin-4 through Akt activation and p70S6K survival signaling pathways

Sue-Jane Lin · Chungming Chang · Ah-Kau Ng ·
Shu-Han Wang · Jia-Je Li · Cheng-po Hu

Published online: 12 July 2007
© Springer Science+Business Media, LLC 2007

Abstract In this study, we demonstrate that interleukin-4 (IL-4) protects human hepatocellular carcinoma (HCC) cell line Hep3B from apoptosis induced by transforming growth factor- β (TGF- β). Further investigation of IL-4-transduced signaling pathways revealed that both insulin response substrate 1 and 2 (IRS-1/-2) and extracellular signal-regulated kinase (ERK) pathways were activated after IL-4 stimulation. The IRS-1/-2 activation was accompanied by the activation of phosphatidylinositol-3-kinase (PI3K), leading to Akt and p70 ribosomal protein S6 kinase (p70S6K). Interestingly, a protein kinase C (PKC)

inhibitor, Gö6976, inhibited the phosphorylation of Akt, suggesting that the Akt activation was PKC-dependent. Using specific inhibitors for PI3K or ERK, we demonstrated that the PI3K pathway, but not the ERK pathway, was required for protection. The constitutively active form of PI3K almost completely rescued TGF- β -induced apoptosis, further supporting the importance of the PI3K pathway in the protective effect of IL-4. Furthermore, a dominant negative Akt and/or Gö6976 only partially blocked the anti-apoptotic effect of IL-4. Similarly, rapamycin, which interrupted the activation of p70S6K, also only partially blocked the protective effect of IL-4. However, in the presence of both rapamycin and dominant negative Akt with or without Gö6976, IL-4 almost completely lost the anti-apoptotic effect, suggesting that both Akt and p70S6K pathways were required for the protective effect of IL-4 against TGF- β -induced apoptosis.

This work was supported by NSC92-2320-B075-012, NSC93-2320-B075-005 and NSC94-2320-B029-002 from the National Science Council, Taiwan, Republic of China. A.-K. Ng was a recipient of Visiting Scholarship from the National Health Research Institutes, Taiwan, Republic of China.

S.-J. Lin · C. Chang · S.-H. Wang · C.-p. Hu
Institute of Microbiology & Immunology, National Yang-Ming University, Taipei, Taiwan, Republic of China

S.-J. Lin · C. Chang · A.-K. Ng
Division of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Miaoli, Taiwan, Republic of China

A.-K. Ng
Department of Applied Medical Science, University of Southern Maine, Portland, ME, USA

J.-J. Li · C.-p. Hu
Department of Medical Research & Education, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China

C.-p. Hu (✉)
Department of Life Science, Tunghai University, 181 Section 3, Taichung Harbor Road, Taichung 40704, Taiwan, Republic of China
e-mail: cphu@thu.edu.tw

Keywords IL-4 · Anti-apoptosis · TGF- β · Akt · p70S6K · Hepatocellular carcinoma cells

Introduction

Transforming growth factor- β (TGF- β) has diverse biological effects on development, proliferation, differentiation, extracellular matrix formation, immune functions and apoptosis [1–6]. The induction of apoptosis by TGF- β has been investigated in many cell types, including T cells, B cells, primary oligodendrocytes, epithelial cells, endothelial cells, hepatocytes and various carcinoma cells [2]. In the liver, TGF- β was found to suppress hepatocyte proliferation in vitro and liver regeneration after partial hepatectomy [7]. It also contributes to the progression of cirrhosis in the liver [8, 9]. Moreover, TGF- β -induced

apoptosis was observed in fetal hepatocytes, primary hepatocytes and human hepatocellular carcinoma (HCC) cell lines [2]. Interleukin-4 (IL-4) has been well-studied for its multiple roles in immune regulation; however, its effect on other biological systems has only become appreciated recently [10, 11]. In the liver, little is known about the mechanism of anti-apoptotic effects of IL-4, a product of Th2 cells, basophils, mast cells and NKT cells [12]. In mice, NKT cells, which account for 30–50% of resident intrahepatic T lymphocytes, can rapidly produce high levels of IL-4 after activation [13]. IL-4 has been reported to protect the liver from ischemia/reperfusion-induced injury through suppression of pro-inflammatory mediators [14, 15]. It also plays a protective role in regulating oxidative damage in the liver during schistosomiasis [16, 17]. Furthermore, IL-4 protects primary T, B, myeloid cells and tumor cells from apoptosis, and prevents human synoviocytes or conjunctival fibroblasts from NO-induced apoptosis [18–22]. These observations suggest that IL-4 has a direct or indirect protective effect on hepatocytes in the liver.

The IL-4R complex specific for different cell types may be composed by IL-4R α and various subunits, including γ_c , IL-13R α 1 or IL-13R α 2 [23–27]. In a previous study, we have demonstrated that IL-4 binds with a high affinity to a HCC cell line Hep3B which expresses an IL-4 receptor complex of IL-4R α , IL-13R α 1 and γ_c [28]. IL-4 stimulation has been linked to several known signaling pathways including the IRS pathway, the signal transducer and activation of transcription 6 (STAT6) pathway and the MAPK pathway. The IRS pathway is mediated by tyrosine phosphorylation of insulin response substrate 1 and 2 (IRS-1/-2) and the activation of the downstream phosphatidylinositol-3-kinase (PI3K), which has consistently been shown to play a significant role in IL-4-mediated cell proliferation [29, 30]. Phosphorylated and dimerized STAT6 widely regulates the expression of IL-4 responsive genes; however, the activation of MAPK pathway by IL-4 is only observed in certain cell types [31], suggesting that MAPK activation is not a universal signaling pathway in cellular response to IL-4. Thus, specific IL-4R complexes which are composed of different subunits on various cell types may trigger various signaling pathways which then contribute to the extensive functions of IL-4.

In this study, we investigated the signaling pathways triggered by IL-4 in Hep3B cells, and examined their potential roles in the protection against apoptosis induced by TGF- β . Our results show that IL-4 protects Hep3B cells from TGF- β -induced apoptosis predominantly through the activation of IRS-PI3K pathway, and a concomitant activation of the downstream Akt and p70S6K signaling pathways.

Materials and methods

Cell culture and transient transfection

Hep3B is a human HCC cell line. The stable transfectant clones, p110*-M, p110*-17, Akt (k-)-M and Akt (k-)-9, were generously provided by Ruey-Hwa Chen,¹ Institute of Molecular Medicine, College of Medicine, National Taiwan University. p110*-M and p110*-17 express a constitutively active form of PI3K [32]; Akt (k-)-M and Akt (k-)-9 express a dominant negative form of Akt [33]. Parental Hep3B cells were cultured in a complete medium containing Dulbecco's modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 IU/ml of penicillin, 100 μ g/ml of streptomycin, 2 mM L-glutamine and 1% non-essential amino acids at 37°C in 5% CO₂. All the stable clones were cultured in the complete medium containing 200 μ g/ml G418. For transient transfection, 1×10^6 Hep3B cells in 2.5-cm plates were washed three times with a serum-free (SF) medium and incubated for 3 h with 4 μ g of plasmid DNA and 32 μ l of Lipofectamine (Invitrogen Corporation, Carlsbad, CA, USA). The culture medium was then changed to fresh DMEM containing 10% FCS. After 18 h, the transfected cells were trypsinized, pooled and re-seeded. After overnight incubation, the cells were cultured in the SF medium for 1 day and then refreshed with SF medium with or without IL-4 for indicated time intervals.

Reagents, antibodies and plasmids

Recombinant human IL-4 was purchased from R&D system (Minneapolis, MN, USA). Recombinant human TGF- β 1 (Austral Biologicals, San Ramon, CA, USA) was reconstituted in 10 mM HCl with 5 mg/ml bovine serum albumin (BSA) and stored in -80°C. PD98059, U0126, rapamycin, wortmannin, LY294002, Gö6850, Gö6976 and Gö6983 were purchased from Calbiochem (La Jolla, CA, USA). Anti-phosphotyrosine (4G10), anti-IRS-1, anti-IRS-2, anti-phospho-p70S6K (Thr-412), anti-Akt, anti-Akt (PH domain, agarose conjugated), anti-phospho-Akt (Ser-473), anti-phospho-Akt (Thr-308), anti-phospho-Bad (Ser-112), and anti-phospho-Bad (Ser-136) antibodies were purchased from Upstate (Charlottesville, VA, USA). Antibodies against ERK-2 (C-14) and Bad were from Santa Cruz (Santa Cruz, CA, USA). Antibodies against phospho-Bad (Ser-155), phospho-Elk-1 (Ser-383) and p70S6K, and Elk-fusion protein were from Cell Signaling Technology

¹ We thank Dr. Ruey-Hwa Chen for providing the stable clones of p110*-M, p110*-17, Akt (k-)-M and Akt (k-)-9 cells and Dr. Cheng-Kung Chou for his helpful discussion and critical reading of this manuscript.

(Beverly, MA, USA). To generate an expression plasmid for human *Bad*, *phBad*, the *Bam*HI–*Xba*I fragment containing the full length cDNA of *Bad* was cloned from Hep3B cells and then inserted into the *Bam*HI–*Xba*I site of the pcDNA3.1 expression vector (Invitrogen).

Apoptosis assay

Apoptosis was determined using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay and the Cell-Death Detection ELISA assay. For the TUNEL assay, the In Situ Death Detection Kit (Roche Applied Science; Penzberg, Germany) was used. In brief, 3×10^5 Hep3B cells seeded in 6-well plates were serum-starved for 48 h and then treated with IL-4 and/or TGF- β for 30 h, 36 h or 42 h. Cells were fixed with 4% paraformaldehyde, and then permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate. The fluorescein-labeled cells were then analyzed by flow cytometry. For the Cell-Death Detection ELISA assay (Roche Applied Science), cells were seeded in 48-well plates at a density of 3×10^4 cells/well and various kinase inhibitors were added to the cells after 2 days of serum starvation. After 2 h, cells were incubated with IL-4 and/or TGF- β in the presence or absence of various kinase inhibitors for 18 h. The presence of soluble histone–DNA complex as a result of DNA fragmentation was measured according to the manufacturer's instructions.

Immunoprecipitation

Hep3B cells were washed twice with ice-cold Hank's balanced salt solution (HBSS), and lysed in the lysis buffer (50 mM Tris–HCl, pH 7.4, 1 mM EDTA, 1% Triton X-100, 2 mM phenylmethylsulfonyl fluoride [PMSF], 2 μ g/ml aprotinin, 1 μ M leupeptin, 1 mM Na_3VO_4 , 80 mM pyrophosphate and 50 mM NaF) on ice. After centrifugation at 12,000g, the pellet was discarded and 1 mg of protein was reacted with 1 μ g of various antibodies at 4°C for 16 h. The immunoprecipitates were mixed with 30 μ l of protein A-Sepharose beads at 4°C for 1 h. The beads were then washed three times with the lysis buffer and added with 30 μ l of boiled 2 \times sample buffer (50 mM Tris–HCl; pH 6.8, 2% SDS, 10% glycerol, 1% 2-mercaptoethanol, 12.5 mM EDTA, 0.02% bromophenol blue). The mixture was then boiled at 100°C for 5 min. The supernatant was subjected to SDS-PAGE.

Western blotting

After SDS-PAGE, the proteins in the acrylamide gel were transferred to nitrocellulose membranes using a semi-dry blotter (Bio-Rad, CA, USA) in the transfer buffer con-

taining 48 mM Tris, pH 8.3, 192 mM glycine, 20% methanol, and 0.0375% SDS. The transfer was conducted under constant current (1 mA per square cm of nitrocellulose membrane) for a period of 1.5–2 h. The membrane was blocked in 5% milk in phosphate-buffered saline (PBS) at 4°C for overnight, incubated with diluted antibodies in 1% milk/PBS at 37°C for 1 h, washed three times with PBS containing 0.05% Tween-20, and reacted with peroxidase-conjugated secondary antibodies at RT for 45 min. The signal was then visualized by ECL system according to the manufacturer's instructions (Pierce Biotechnology, Inc; Rockford, IL, USA).

Phosphatidylinositol 3-kinase (PI3K) assay

For the PI3K assay, 2.5×10^6 cells were lysed in 0.5 ml of the lysis buffer used for immunoprecipitation described before. After centrifugation at 12,000g, the pellet was discarded and 1 mg of protein was pre-incubated with 30 μ l protein A-Sepharose at 4°C for 1 h and the protein A-Sepharose was discarded after centrifugation. The supernatant was reacted with 1 μ g of anti-phosphotyrosine antibody (4G10) and 30 μ l of protein A-Sepharose beads at 4°C for overnight. After the immunoprecipitates were washed three times with the lysis buffer, twice with LiCl buffer (100 mM Tris, pH 7.6, 0.5 M LiCl), and twice with TNE buffer (10 mM Tris, pH 7.6, 100 mM NaCl, 1 mM EDTA), 10 μ l of phosphatidylinositol (Sigma, 2 mg/ml in 20 mM HEPES, pH 7.4) were incubated with the beads for 10 min on ice. The kinase reaction was then initiated by the addition of 40 μ l of the reaction buffer (20 mM HEPES, pH 7.4, 10 mCi [γ - 32 P] ATP, 20 mM ATP, 5 mM MgCl_2) at RT for 15 min and stopped by an addition of 100 μ l of 1 N HCl. The mixture was then added with 200 μ l of chloroform/methanol with a 1:1 ratio. The extracted lipid in the organic phase was spotted onto a thin-layer chromatography plate and developed in chloroform/methanol/4 M NH_4OH (9:7:2). The labeled phosphatidylinositol 3-phosphate (PI3-P) was then visualized by autoradiography.

Extracellular signal-regulated kinase (ERK) assay

Hep3B cells were cultured with or without PD98059 or U0126 after 2 days of serum starvation. After 2 h, cells were incubated with IL-4 (100 ng/ml) for 15 min, washed twice with cold HBSS and then lysed in the buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM NaF, 1 mM Na_3VO_4 , 1 μ g/ml leupeptin, 2 mM PMSF and 1 mM β -glycerolphosphate on ice for 5 min. After centrifugation at 12,000g, the pellet was discarded and 200 μ g of protein were reacted with 2 μ g of anti-ERK-2 antibody at 4°C for 3 h. The immunoprecipitates were mixed with 30 μ l of

protein A-Sepharose beads for 1 h, washed twice with the lysis buffer, twice with the kinase buffer (25 mM Tris, pH 7.5, 0.1 mM Na_3VO_4 , 5 mM β -glycerolphosphate, 2 mM DTT and 10 mM MgCl_2), and suspended in 48 μl of the kinase buffer containing 200 μM ATP and 2 μg of the substrate Elk-fusion protein. The kinase reaction was carried out at 30°C for 30 min and terminated by the addition of 12.5 μl of 5 \times sample buffer. After boiling, 30 μl of the sample was subjected to SDS-PAGE and immunoblotting analysis with anti-phospho-Elk-1 (Ser-383) antibody.

Results

IL-4 protects Hep3B cells from TGF- β -induced apoptosis

To investigate the anti-apoptotic effect of IL-4 on HCC cells, Hep3B cells were treated with TGF- β in the presence or absence of IL-4. As measured by the TUNEL assay, Fig. 1A shows that TGF- β induces apoptosis at 30 h, 36 h and 42 h, and IL-4 almost completely rescues Hep3B cells from apoptosis (52.95% TUNEL positive cells after TGF- β treatment versus 1.92% TUNEL positive cells after combined treatment of TGF- β and IL-4). We further verified the anti-apoptotic ability of IL-4 using a cell death detection ELISA kit which measures the soluble histone–DNA complex resulting from DNA fragmentation (Fig. 1B). These results convincingly demonstrate that IL-4 prevents TGF- β -induced apoptosis in Hep3B cells.

Activation of IRS/PI3K pathway is critical to the anti-apoptotic effect of IL-4

To investigate the mechanisms underlying the reversing effect of IL-4 on apoptosis, we attempted to characterize the signaling pathways transduced by IL-4 in Hep3B cells. As shown in Fig. 2A, we found that IL-4 activated IRS-1 and IRS-2 in Hep3B cells at 5 and 15 min after incubation. To examine the contribution of various signaling pathways to the anti-apoptotic effect of IL-4, we measured the direct activation of signaling molecules in the presence of specific inhibitors. Our data demonstrated that IL-4 stimulation activated PI3K in Hep3B cells, as measured by a standard PI3K assay, and this activation was blocked by 5 μM wortmannin, a specific inhibitor of PI3K (Fig. 2B). These results prompted us to investigate whether PI3K activation was involved in the anti-apoptotic effect of IL-4. In Hep3B cells treated with 0.2, 2, 5 μM wortmannin (Fig. 2C) or 0.5, 2, 10 μM LY294002, another specific inhibitor of PI3K (Fig. 2D), the IL-4-mediated prevention of TGF- β -induced apoptosis was blocked in a dose-dependent manner. To further verify the involvement of PI3K in the anti-apoptotic effect of IL-4, we used two stable clones of Hep3B cells expressing constitutively activated PI3K, p110*-M and p110*-17, wherein the iSH2 domain of the p85 subunit was fused to the p110 subunit. The results indicated that the p110*-M cells were completely resistant to TGF- β -induced apoptosis (Fig. 2E). However, the p110*-17 clone, which expressed a lower amount of the constitutively activated PI3K (data not shown), was less




Fig. 1 IL-4 prevents TGF- β -induced apoptosis. (A) Hep3B cells were seeded in 6-well plates at a density of 3×10^5 cells/well. After 2 days of serum starvation, cells were fed with fresh SF medium without or with IL-4 (100 ng/ml), TGF- β (5 ng/ml) or IL-4 plus TGF- β . Apoptotic cells were measured by TUNEL assay at 30, 36 and 42 h by flow cytometry [Negative control (black histogram), incubated

with label solution, in the absence of terminal transferase, Test sample (blank histogram), incubated with TUNEL reaction mixture] or (B) Hep3B cells were seeded in 48-well plates at a density of 3×10^4 cells/well and were cultured as described above. Apoptotic cells were measured by a Cell-Death Detection ELISA at 18 h. This is representative of two similar experiments




Fig. 2 Activation of IRS/PI3K pathway is required for the anti-apoptotic effect of IL-4. (A) Hep3B cells were treated with IL-4 at indicated times. Cell lysates with equal amounts of protein were immunoprecipitated with anti-IRS-1 or anti-IRS-2 antibody. The immunoprecipitates were subjected to SDS-PAGE and immunoblotting with anti-phosphotyrosine antibody (4G10). The membranes were then stripped and reused for immunoblottings with anti-IRS-1 or anti-IRS-2 antibody to verify equal amounts of IRS-1 or IRS-2 in all samples. (B) Hep3B cells were treated with IL-4 for 5 min. Lysates of Hep3B cells treated with IL-4 alone or in the presence of PI3K inhibitor, wortmannin, were immunoprecipitated with anti-phosphotyrosine antibody (4G10). The immunoprecipitates were incubated with phosphatidylinositol (PI) and P³²-γATP. The lipid products were then analyzed by thin-layer chromatography and autoradiography. (C) and (D) Hep3B cells were cultured as described in Fig. 1B. PI3K inhibitors wortmannin (C) or LY294002 (D) were added to the cells after 2 days of serum starvation. After 2 h, cells were incubated with IL-4 (100 ng/ml), TGF-β (5 ng/ml) or IL-4 plus TGF-β. Apoptotic cells were measured as described in Fig. 1B. (E) Hep3B cells or stable clones (p110^{*}-M, p110^{*}-17) expressing the constitutively active form of PI3K were treated with TGF-β (5 ng/ml), and apoptotic cells were measured as described in Fig. 1B (*P* value was analyzed by *t*-test). Independent experiments were repeated three times and showed similar results

resistant. Collectively, these findings provide evidences that IL-4-mediated PI3K activation plays an important role in the prevention of TGF-β-induced apoptosis in Hep3B cells.

ERK pathway is not involved in the anti-apoptotic effect of IL-4

Figure 3A shows that ERK in MAPK signal cascades is also activated by IL-4 treatment, and this activation of ERK can be blocked by its inhibitors, PD98059 or U0126. However, neither PD98059 nor U0126 inhibited the anti-apoptotic effect of IL-4 (Fig. 3B), suggesting that IL-4-induced activation of ERK does not transduce an anti-apoptotic signaling against TGF-β-induced apoptosis in Hep3B cells.

Akt is required for IL-4-mediated prevention of TGF-β-induced apoptosis

To understand how PI3K signaling contributes to the IL-4-mediated prevention of TGF-β-induced apoptosis, we investigated next whether Akt was involved in the downstream signalings of PI3K pathway which contributes to the IL-4-mediated prevention of TGF-β-induced apoptosis.




Fig. 3 ERK pathway is not involved in the anti-apoptotic effect of IL-4. (A) Hep3B cells were treated with IL-4 for 15 min alone or in the presence of ERK inhibitors. Lysates of Hep3B cells treated with IL-4 alone or in the presence of ERK inhibitors, PD98059 or U0126, were immunoprecipitated with anti-ERK-2 antibody. The immune complexes were resuspended in the kinase buffer containing ATP and Elk-1 fusion protein substrate. After reaction, the samples were subjected to SDS-PAGE and immunoblotting with anti-phospho-Elk-1 (Ser-383) antibody or anti-ERK-2 antibody. (B) Apoptotic cells were measured as described in Fig. 1B. Various concentrations of ERK inhibitors, PD98059 or U0126 was added into the cells after 2 days of serum starvation. After 2 h, cells were incubated with IL-4 (100 ng/ml), TGF-β (5 ng/ml) or IL-4 plus TGF-β. Independent experiments were repeated two times and showed similar results

Our results demonstrated that IL-4 induced the phosphorylation of Akt at Ser-473 at 15 min, and the phosphorylation was completely blocked by 5 μ M wortmannin or 10 μ M LY294002 (Fig. 4A). To address the role of Akt in the anti-apoptotic effect of IL-4, two stable Hep3B transfectants Akt (k-)-M and Akt (k-)-9, which expressed dominant negative Akt, were employed. As shown in Fig. 4B, the expression of dominant negative form of Akt partially suppressed the preventive effect of IL-4 on the TGF- β -induced apoptosis (enhancing cell death from 20% to 43% and 46% in Akt (k-)-9 and Akt (k-)-M clones, respectively). This observation implies that other anti-apoptotic mechanisms may also be involved.

PKC is involved in the anti-apoptotic effects of IL-4

To address whether protein kinase C (PKC) participates in the downstream signaling of PI3K, we investigated the effect of IL-4 on TGF- β -induced apoptosis in the presence of three PKC inhibitors; Gö6976 (inhibits PKC α , β 1, μ), Gö6983 (inhibits PKC α , β , γ , δ) and Gö6850 (inhibits PKC α , β 1/2, δ , γ , ϵ). We found that 2.5 μ M of Gö6976 partially reversed the anti-apoptotic effect of IL-4, (Fig. 5A), increasing cell death from 30% to 66%, whereas Gö6850 and Gö6983 had no effect on the IL-4-dependent protection (data not shown). To examine whether PKC is related to the Akt pathway, we studied the effect of PKC

inhibitor, Gö6976, on the anti-apoptotic effect of IL-4 in Akt (k-)-M cells expressing dominant negative Akt. Interestingly, Gö6976 did not further reverse IL-4's protective effect in Akt (k-)-M cells (Fig. 5B, 56.5% cell death for the control vs. 62% cell death for the treated, $P = 0.2$). (Fig. 5B) These results suggest that the anti-apoptotic signalings induced by Akt and PKC may originate from a common pathway. Furthermore, the IL-4-induced phosphorylation of Akt at Ser-473 and Thr-308 could not be detected in Akt (k-)-M cells after treatment of Gö6976 (Fig. 5C). These results indicate that PKC may be an upstream signaling molecule of Akt, and PKC-mediated Akt activation is involved in the anti-apoptotic effect of IL-4.

p70S6K pathway is involved in IL-4-mediated prevention of apoptosis

To further elucidate whether the p70S6K pathway, a downstream signaling molecule of PI3K, is activated by IL-4, Western blotting with an anti-phospho-p70S6K antibody was performed. As shown in Fig. 6A, IL-4 treatment results in the phosphorylation of p70S6K at Thr-412 at 15 min. Rapamycin which interferes with the activation of p70S6K also blocks the phosphorylation of p70S6K. Furthermore, two PI3K inhibitors, 5 μ M wortmannin or 10 μ M LY294002, also inhibit the phosphorylation of p70S6K. These results indicated that p70S6K is also a downstream molecule of PI3K after IL-4 stimulation. To test whether p70S6K participates in the anti-apoptotic function of IL-4, various concentrations (2, 10 and 50 nM) of rapamycin were employed. Results in Fig. 6B demonstrate that 50 nM of rapamycin partially reverse the prevention of IL-4 on TGF- β induced apoptosis (raising cell death from 24% to 44%); indicating that p70S6K pathway may also participate in the anti-apoptotic effect of IL-4. To discern whether the p70S6K pathway runs in parallel to the Akt pathway, we measured the effect of rapamycin in Akt (k-)-M cells which expressed a dominant negative Akt. As shown in Fig. 6C, 50 nM of rapamycin blocked the basal level and the IL-4-induced activation of p70S6K in Akt (k-)-M cells. Similarly, rapamycin impaired the anti-apoptotic effect of IL-4 in Akt (k-)-M cells; enhancing cell death from 55% to 78% (Fig. 6D). These results indicate that p70S6K is activated through a PI3K-dependent manner and the PI3K-dependent p70S6K pathway is involved in the anti-apoptotic effect of IL-4 on TGF- β -induced apoptosis in Hep3B cells. To further demonstrate the participation of PKC-mediated Akt and p70S6K as survival signaling molecules in IL-4's anti-apoptotic effect, we studied the combined effect of Gö6976 and rapamycin on the IL-4 action. These two inhibitors completely reversed the anti-apoptotic effect of IL-4 on TGF- β -induced apoptosis in Akt (k-)-M cells (Fig. 6E, increasing cell




Fig. 4 Akt is involved in the anti-apoptotic effect of IL-4. (A) Hep3B cells were treated with IL-4 for 15 min alone or in the presence of PI3K inhibitors, wortmannin or LY294002. Cell lysates with equal amounts of protein were subjected to immunoblottings with anti-phospho-Akt (Ser-473) antibody. The membrane was then stripped and immunoblotted with anti-Akt antibody. (B) Apoptosis of Hep3B cells and stable clones Akt (k-)-M; Akt (k-)-9 expressing a dominant negative Akt were measured as described in Fig. 1B. Independent experiments were repeated three times and showed similar results




Fig. 5 PKC inhibitor, Gö6976, inhibits the anti-apoptotic effect of IL-4 and the activation of Akt. Apoptosis of (A) Hep3B cells and (B) stable clones Akt (k-)-M cells were measured as described in Fig. 1B. PKC inhibitor, Gö6976 was added to the cells after 2 days of serum starvation. After 2 h, cells were incubated with IL-4 (100 ng/ml), TGF- β (5 ng/ml) or IL-4 plus TGF- β . (C) Hep3B cells were treated with IL-4 for 15 min alone or in the presence of Gö6976. Lysates of

IL-4 treated Hep3B cells with equal amounts of protein were immunoprecipitated with anti-Akt (PH domain, agarose conjugate). The immunoprecipitates were subjected to SDS-PAGE and immunoblotting with anti-phospho-Akt (Ser-473) or anti-phospho-Akt (Thr-308) antibodies. The membrane was then stripped and immunoblotted with anti-Akt antibody. Independent experiments were repeated three times and showed similar results

death from 58% to 94%) and in Hep3B cells (Fig. 6F, increasing cell death from 32% to 91%). Thus, these results demonstrate that PKC-transduced Akt and p70S6K survival pathways are necessary and sufficient for the IL-4-mediated inhibition of TGF- β -induced apoptosis.

Both Akt and p70S6K pathways contribute to IL-4-induced phosphorylation of Bad at Ser-136

It has been reported that Akt and p70S6K phosphorylate Bad at Ser-136, leading to prevent the cell death [34–36]. Our results demonstrated that Bad remained constant expression level after either IL-4 or TGF- β treatment at 2, 4, 6 and 8 h (Fig. 7A); suggesting that IL-4's preventive effects is not due to decreased expression of Bad. To detect specific phosphorylation sites of Bad after IL-4 stimulation, we overexpressed Bad protein in Hep3B cells. IL-4 stimulation resulted in the phosphorylation of Bad at Ser-112 and Ser-136 (Fig. 7B). To explore the molecular link between IL-4-induced survival signaling and Bad phosphorylation, we first examined the effect of PI3K inhibitors, wortmannin, LY294002 on IL-4-induced phosphorylation

of Bad. As shown in the Fig. 7C, phosphorylation of Bad at Ser-112 and Ser-136 was blocked by wortmannin or LY294002, suggesting that the PI3K pathway is required for IL-4-induced phosphorylation of Bad at Ser-112 and Ser-136. Next, we attempted to understand the involvement of p70S6K and Akt in the phosphorylation of Bad. The results in Fig. 7C show that p70S6K inhibitor, rapamycin, also blocks the phosphorylation of Bad at Ser-112 and Ser-136. However, Fig. 7D shows that, in Akt (k-)-M cells, IL-4 failed to induce the phosphorylation of Bad at Ser-136, but still induced the phosphorylation of Bad at Ser-112. Thus, both Akt and p70S6K pathways seem to be required for IL-4-induced phosphorylation of Bad at Ser-136, whereas only the latter pathway participates in the phosphorylation of Bad at Ser-112.

Discussion

IL-4 regulates a wide variety of biological functions. Other than its well studied function as a Th2 cytokines, IL-4 acts as a survival factor in a number of cell types, including




Fig. 6 The p70S6K pathway is involved in the anti-apoptotic effect of IL-4. **(A)** Hep3B cells were treated with IL-4 for 15 min alone or in the presence of various kinase inhibitors. Lysates of IL-4 treated Hep3B cells were subjected to SDS-PAGE and immunoblotting with anti-phospho-p70S6K (Thr-412) and anti-p70S6K antibodies. **(B)** Apoptosis of Hep3B cells was measured as described in Fig. 1B. Rapamycin was added to the cells after 2 days of serum starvation. **(C)** Akt (k-)-M cells were treated with IL-4 for 15 min alone or in the presence of rapamycin. Lysates of IL-4 treated Akt (k-)-M cells were

subjected to SDS-PAGE and immunoblotting with anti-phospho-p70S6K (Thr-412) and anti-p70S6K antibodies. **(D)**, **(E)** and **(F)** Apoptosis of Akt (k-)-M cells **(D and E)** and Hep3B cells **(F)** were measured as described in Fig. 1B. Rapamycin and G66976 were added to the cells after 2 days of serum starvation. After 2 h, cells were incubated with IL-4 (100 ng/ml), TGF- β (5 ng/ml) or IL-4 plus TGF- β . Independent experiments were repeated three times and showed similar results

T cells, B cells, myeloid cells, synovocytes, endothelial cells, fibroblasts and cancer cells [19, 21, 37–41]. In the liver, IL-4 has been reported to inhibit ischemia/reperfusion induced liver injury, through the suppression of pro-inflammatory mediators [14]. IL-4 also protects against TNF- α -mediated oxidative damage and apoptosis during schistosomiasis [17]. However, it remains uncertain whether IL-4 has a direct or an indirect protective effect on the apoptosis of hepatocellular carcinoma cells. Unlike IL-4, TGF- β , on the other hand, serves as a negative mediator of liver homeostasis by promoting apoptosis, and inhibiting proliferation or regeneration in liver cells. Previous studies have been reported that several pro-apoptotic processes, including production of reactive oxygen species (ROS), activation of caspase-3, -8 and -9, downregulation of Bcl-2 and Bcl-X_L expression and activation of Smad-2, -3 and -4

dependent pathways, are involved in TGF- β -mediated apoptotic death in cultured hepatocytes and HCC cells [3]. To gain insight into combined effects of liver cytokines in diseases, this study has focused on elucidating the survival signaling pathways mediated by IL-4, using the model of TGF- β -induced apoptosis in Hep3B cells.

The IRS-PI3K, MAPK and STAT6 signaling pathways delivered through IL-4 receptors (IL-4R) have been extensively studied in various cell types. Our results demonstrated that IRS-1/-2 (Fig. 2A), ERK (Fig. 3A) and STAT6 (data not shown) pathways were activated by IL-4 in Hep3B cells. We further demonstrated that PI3K, a downstream signaling molecule of IRS-1/-2, was also activated using an in vitro PI3K assay and that the anti-apoptotic effect of IL-4 was mainly mediated through the PI3K pathway (Fig. 2C–E). However, IL-4-induced





Fig. 7 Both Akt and p70S6K pathways are required for IL-4-induced phosphorylation of Bad at Ser-136. **(A)** Hep3B cells were seeded in 6-cm plate at a density of 1×10^6 cells /plate. After 2 days of serum starvation, cells were incubated with IL-4 (100 ng/ml), TGF- β (5 ng/ml) or IL-4 plus TGF- β at indicated time points. Lysates of Hep3B cells were harvested. Western blotting analysis of Bad was performed. The same membranes were re-hybridized with anti- α -tubulin Ab to quantitate the amount of protein in each lane. **(B, C, D)** The plasmid containing human Bad, phBad, was transfected to Hep3B cells and Akt (k-)-M cells. After 18 h, the cells were pooled, re-seeded and cultured in SF medium for 1 day. IL-4 (100 ng/ml) was added into the culture for indicated times. Cell lysates were prepared and subjected to immunoblottings with anti-phospho-Bad (Ser-112) and anti-phospho-Bad (Ser-136) antibodies. **(B)** Bad transfected Hep3B cells treated with or without IL-4. **(C)** Bad transfected Hep3B cells treated with IL-4 together wortmannin, LY294002 or rapamycin. **(D)** Bad transfected Akt (k-)-M cells treated with or without IL-4. The membranes were then stripped and immunoblotted with anti-Bad antibody. Independent experiments were repeated two times and showed similar results

activation of ERK pathway was not involved in the prevention of TGF- β -induced apoptosis (Fig. 3A, B). Although STAT6 can be activated by IL-4 in Hep3B cells (data not shown), we do not know whether it is required for the protective effect of IL-4 at the present time.

Akt, a downstream signaling molecule of PI3K, plays an important role in survival mechanisms mediated by various growth factors [42, 43]. However, dominant negative Akt only partially blocked the anti-apoptotic effect of IL-4 (Fig. 4B). These findings suggest that other signaling pathways may be involved. We found that Gö6976, an inhibitor for PKC α , β (and μ isoforms), could partially block the anti-apoptotic effect of IL-4. However, it did not further decrease the anti-apoptotic effect of IL-4 in Akt (k-)-M cells expressing dominant negative Akt. Interestingly, Gö6976 also inhibited the IL-4-induced phosphorylation of Akt (Fig. 5C). These results suggest that Akt lies in the downstream of PKC. Previous reports have shown that PKC α or PKC β were involved in the induction of Akt phosphorylation [44–46]. However, our results indicated that IL-4 could not induce the membrane translocation of PKC α , β and μ in Hep3B cells, suggesting that those kinases were not activated (data not shown). Thus, it is possible that other PKC isoforms are activated by IL-4 stimulation and their kinase activity is inhibited by Gö6976.

Previous studies have reported that p70S6K is a downstream signaling molecule of PI3K, but it is not required for IL-4-promoted survival of myeloid cells [47]. Our results showed that IL-4 stimulation induced the phosphorylation of p70S6K, which could be blocked by PI3K inhibitors, wortmannin and LY294002, indicating that p70S6K was at the downstream of PI3K (Fig. 6A). We further showed that p70S6K partially contributed to the anti-apoptotic effect of IL-4 (Fig. 6B) and that blocking of p70S6K activation by rapamycin could further decrease the anti-apoptotic effect of IL-4 in Hep3B cells expressing dominant negative Akt (Fig. 6D). In addition, treatment with Gö6976 and rapamycin almost completely blocked the anti-apoptotic effect of IL-4 in parental Hep3B cells and Hep3B cells expressing dominant negative Akt (Fig. 6E, F). Thus, Akt and p70S6K concertedly achieved full maximal anti-apoptotic effect of IL-4.

Activated Akt or p70S6K could phosphorylate an apoptotic molecule Bad at Ser-136 [34, 48]; however, some studies reported that IL-4-activated Akt did not induced Bad phosphorylation [49, 50]. We found that IL-4-induced phosphorylation of Ser-112 and Ser-136 (Fig. 7A), but not at Ser-155 (data not shown) in Hep3B cells overexpressing Bad. Furthermore, treatment of wortmannin, LY294002 (PI3K inhibitors) and rapamycin (p70S6K inhibitor) resulted in the inhibition of Bad phosphorylation at Ser-112 and Ser-136. We also found that IL-4 could not induce the phosphorylation of Bad at Ser-136 in Akt (k-)-M cells. Thus, the phosphorylation of Ser-136 seemed to be dependent on both Akt and p70S6K pathways. Previous studies demonstrated that Bad phosphorylation at Ser-112 is through the activation of ERK-1/2 [36]. However, IL-4



Proposed model of IL-4 signaling pathways in Hep3B cells

Fig. 8 Proposed model of IL-4 survival signaling pathways in Hep3B cells. Following the activation of IRS/PI3K pathway through IL-4 and IL-4R complex interaction, activated PI3K contributed to the PKC-mediated Akt activation and p70S6K signaling pathways. While both pathways could phosphorylate apoptotic molecule, Bad, at Ser-136, only p70S6K participated in the phosphorylation of Bad at Ser-112. In summary, Akt and p70S6K signaling pathways were both necessary and sufficient for the inhibition of TGF- β -induced apoptosis

could induce the activation of ERK, but this pathway did not contribute to prevent cell death by IL-4 (Fig. 3A, B). Thus, it will be interesting to explore whether p70S6K is directly responsible for phosphorylating Bad at Ser-112 in Hep3B cells.

It has been reported that various survival factors could suppress TGF- β -induced apoptosis in hepatocytes and HCC cells [32, 33, 51, 52]. Various signaling pathways, e.g. PI3K/Akt, STAT3, ERK or p38 pathways, have been demonstrated in transducing the survival signalings. Our study further shows IL-4 as another survival factor in the liver.

Recently, the crosstalk between insulin and TGF- β signaling pathways was found to be linked by Akt and Smad-3 pathways in Hep3B cells [50, 53]. To elucidate how IL-4-mediated signals might counteract with cellular response to TGF- β , we examined the direct effect of IL-4 on Smad-3-induced activation and transcription using the 3TP-Lux plasmid system. Our result demonstrated that IL-4 has no effect on TGF- β -induced Smad-3-regulated transcription (data not shown). Moreover, previous study has shown that Smad-mediated induction of death-associated protein kinase (DAPK) contributed to TGF- β -induced apoptosis [54]. In our system, however, neither could TGF- β induce the expression of DAPK, nor IL-4 altered the expression level of DAPK (data not shown). Thus, these results suggest that the anti-apoptotic effect of IL-4 may

not be attributable to its direct interference with cellular responses to TGF- β stimulation.

Conclusion

This study with HCC has yielded several helpful hints to elucidate the anti-apoptotic mechanism of IL-4 in HCC cells and the finding may be applicable to hepatocytes. Our results indicated that either the Akt pathway or the p70S6K survival pathway alone was only partially effective in IL-4-mediated protection of Hep3B cells from TGF- β -induced apoptosis. In conclusion, the two pathways appear able to function cooperatively to achieve the maximal anti-apoptotic effect of IL-4 in Hep3B cells (Fig. 8). It remains to be explored, however, if the anti-apoptotic effect in vitro of IL-4, a product of T, B and NKT cells in liver, serves any physiological role in vivo. All these studies have provided strong evidence to suggest that IL-4 could protect hepatocytes from cellular programming that leads to apoptosis.

References

1. Moustakas A (2002) Smad signalling network. *J Cell Sci* 115:3355–3356
2. Sanchez-Capelo A (2005) Dual role for TGF-beta1 in apoptosis. *Cytokine Growth Factor Rev* 16:15–34
3. Schuster N, Krieglstein K (2002) Mechanisms of TGF-beta-mediated apoptosis. *Cell Tissue Res* 307:1–14
4. Miyazono K, Suzuki H, Imamura T (2003) Regulation of TGF-beta signaling and its roles in progression of tumors. *Cancer Sci* 94:230–234
5. Roberts AB, Wakefield LM (2003) The two faces of transforming growth factor beta in carcinogenesis. *Proc Natl Acad Sci USA* 100:8621–8623
6. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell* 113:685–700
7. Inagaki M, Moustakas A, Lin HY et al (1993) Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA. *Proc Natl Acad Sci USA* 90:5359–5363
8. Michalopoulos GK, DeFrances MC (1997) Liver regeneration. *Science* 276:60–66
9. Gressner AM, Weiskirchen R, Breitkopf K et al (2002) Roles of TGF-beta in hepatic fibrosis. *Front Biosci* 7:d793–d807
10. Charge S, Rudnicki MA (2003) Fusion with the fused: a new role for interleukin-4 in the building of muscle. *Cell* 113:422–423
11. Horsley V, Jansen KM, Mills ST et al (2003) IL-4 acts as a myoblast recruitment factor during mammalian muscle growth. *Cell* 113:483–494
12. Nelms K, Keegan AD, Zamorano J et al (1999) The IL-4 receptor: signaling mechanisms and biologic functions. *Annu Rev Immunol* 17:701–738
13. Godfrey DI, Hammond KJ, Poulton LD et al (2000) NKT cells: facts, functions and fallacies. *Immunol Today* 21:573–583
14. Kato A, Yoshidome H, Edwards MJ et al (2000) Reduced hepatic ischemia/reperfusion injury by IL-4: potential anti-inflammatory role of STAT6. *Inflamm Res* 49:275–279

15. Kato A, Yoshidome H, Edwards MJ et al (2000) Regulation of liver inflammatory injury by signal transducer and activator of transcription-6. *Am J Pathol* 157:297–302
16. Brunet LR, Finkelman FD, Cheever AW et al (1997) IL-4 protects against TNF-alpha-mediated cachexia and death during acute schistosomiasis. *J Immunol* 159:777–785
17. La Flamme AC, Patton EA, Bauman B et al (2001) IL-4 plays a crucial role in regulating oxidative damage in the liver during schistosomiasis. *J Immunol* 166:1903–1911
18. Aronica MA, Goenka S, Boothby M (2000) IL-4-dependent induction of BCL-2 and BCL-X(L) in activated T lymphocytes through a STAT6- and pi3-kinase-independent pathway. *Cytokine* 12:578–587
19. Foote LC, Howard RG, Marshak-Rothstein A et al (1996) IL-4 induces Fas resistance in B cells. *J Immunol* 157:2749–2753
20. Zamorano J, Keegan AD (1998) Regulation of apoptosis by tyrosine-containing domains of IL-4R alpha: Y497 and Y713, but not the STAT6-docking tyrosines, signal protection from apoptosis. *J Immunol* 161:859–867
21. Relic B, Guicheux J, Mezin F et al (2001) IL-4 and IL-13, but not IL-10, protect human synoviocytes from apoptosis. *J Immunol* 166:2775–2782
22. Fujitsu Y, Fukuda K, Kimura K et al (2005) Protection of human conjunctival fibroblasts from NO-induced apoptosis by interleukin-4 or interleukin-13. *Invest Ophthalmol Vis Sci* 46:797–802
23. Russell SM, Keegan AD, Harada N et al (1993) Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. *Science* 262:1880–1883
24. Zurawski SM, Vega F Jr, Huyghe B et al (1993) Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. *Embo J* 12:2663–2670
25. Hilton DJ, Zhang JG, Metcalf D et al (1996) Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. *Proc Natl Acad Sci USA* 93:497–501
26. Murata T, Taguchi J, Puri RK (1998) Interleukin-13 receptor alpha' but not alpha chain: a functional component of interleukin-4 receptors. *Blood* 91:3884–3891
27. Lowenthal JW, Castle BE, Christiansen J et al (1988) Expression of high affinity receptors for murine interleukin 4 (BSF-1) on hemopoietic and nonhemopoietic cells. *J Immunol* 140:456–464
28. Lin SJ, Shu PY, Chang C et al (2003) IL-4 suppresses the expression and the replication of hepatitis B virus in the hepatocellular carcinoma cell line Hep3B. *J Immunol* 171:4708–4716
29. Kelly-Welch AE, Hanson EM, Boothby MR et al (2003) Interleukin-4 and interleukin-13 signaling connections maps. *Science* 300:1527–1528
30. Myers MG Jr, Grammer TC, Wang LM et al (1994) Insulin receptor substrate-1 mediates phosphatidylinositol 3'-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. *J Biol Chem* 269:28783–28789
31. Wery S, Letourneur M, Bertoglio J et al (1996) Interleukin-4 induces activation of mitogen-activated protein kinase and phosphorylation of shc in human keratinocytes. *J Biol Chem* 271:8529–8532
32. Chen RH, Su YH, Chuang RL et al (1998) Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway. *Oncogene* 17:1959–1968
33. Chen RH, Chang MC, Su YH et al (1999) Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. *J Biol Chem* 274:23013–23019
34. Datta SR, Dudek H, Tao X et al (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. *Cell* 91:231–241
35. Tan Y, Demeter MR, Ruan H et al (2000) BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. *J Biol Chem* 275:25865–25869
36. Scheid MP, Schubert KM, Duronio V (1999) Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. *J Biol Chem* 274:31108–31113
37. Vella A, Teague TK, Ihle J et al (1997) Interleukin 4 (IL-4) or IL-7 prevents the death of resting T cells: stat6 is probably not required for the effect of IL-4. *J Exp Med* 186:325–330
38. Zamorano J, Wang HY, Wang LM et al (1996) IL-4 protects cells from apoptosis via the insulin receptor substrate pathway and a second independent signaling pathway. *J Immunol* 157:4926–4934
39. Conticello C, Pedini F, Zeuner A et al (2004) IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. *J Immunol* 172:5467–5477
40. Vella V, Mineo R, Frasca F et al (2004) Interleukin-4 stimulates papillary thyroid cancer cell survival: implications in patients with thyroid cancer and concomitant Graves' disease. *J Clin Endocrinol Metab* 89:2880–2889
41. Grehan JF, Levay-Young BK, Fogelson JL et al (2005) IL-4 and IL-13 induce protection of porcine endothelial cells from killing by human complement and from apoptosis through activation of a phosphatidylinositol 3-kinase/Akt pathway. *J Immunol* 175:1903–1910
42. Franke TF, Hornik CP, Segev L et al (2003) PI3K/Akt and apoptosis: size matters. *Oncogene* 22:8983–8998
43. Harada N, Hatano E, Koizumi N et al (2004) Akt activation protects rat liver from ischemia/reperfusion injury. *J Surg Res* 121:159–170
44. Li W, Zhang J, Flechner L et al (1999) Protein kinase C-alpha overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawal. *Oncogene* 18:6564–6572
45. Partovian C, Simons M (2004) Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. *Cell Signal* 16:951–957
46. Barragan M, de Frias M, Iglesias-Serret D et al (2006) Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C β . *J Leukoc Biol* 80:1473–1479
47. Minshall C, Arkins S, Dantzer R et al (1999) Phosphatidylinositol 3'-kinase, but not S6-kinase, is required for insulin-like growth factor-I and IL-4 to maintain expression of Bcl-2 and promote survival of myeloid progenitors. *J Immunol* 162:4542–4549
48. Harada H, Andersen JS, Mann M et al (2001) p70S6 kinase signals cell survival as well as growth, inactivating the proapoptotic molecule BAD. *Proc Natl Acad Sci USA* 98:9666–9670
49. Wurster AL, Rodgers VL, White MF et al (2002) Interleukin-4-mediated protection of primary B cells from apoptosis through Stat6-dependent up-regulation of Bcl-xL. *J Biol Chem* 277:27169–27175
50. Conery AR, Cao Y, Thompson EA et al (2004) Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. *Nat Cell Biol* 6:366–372
51. Fabregat I, Herrera B, Fernandez M et al (2000) Epidermal growth factor impairs the cytochrome C/caspase-3 apoptotic pathway induced by transforming growth factor beta in rat fetal hepatocytes via a phosphoinositide 3-kinase-dependent pathway. *Hepatology* 32:528–535
52. Roberts RA, James NH, Cosulich SC (2000) The role of protein kinase B and mitogen-activated protein kinase in epidermal

- growth factor and tumor necrosis factor alpha-mediated rat hepatocyte survival and apoptosis. *Hepatology* 31:420–427
53. Remy I, Montmarquette A, Michnick SW (2004) PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. *Nat Cell Biol* 6:358–365
54. Jang CW, Chen CH, Chen CC et al (2002) TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. *Nat Cell Biol* 4:51–58